Plasmonic Biosensor Nanoparticle-Enhanced Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional nanoplasmonic biosensors face limitations in sensitivity and scalability due to complex optical read-out requirements and non-specific interactions, particularly in detecting biomarkers at clinically relevant concentrations, with Au-NHAs only achieving detection of 4 μg/ml protein, which is above most biomarker concentrations.
Innovation Solution
A nanoparticle-enhanced plasmonic biosensor system using gold nano-hole arrays (Au-NHAs) that visualizes single sub-wavelength nanoparticles under bright-field imaging, enabling digital quantification and localization of individual nanoparticle-labeled molecules through local extraordinary optical transmission quenching, allowing for the detection of biomarkers at much lower concentrations, such as 10 pg/ml for biotinylated bovine serum albumin and 27 pg/ml for human C-reactive protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional nanoplasmonic biosensors use Au-NHAs with spectral data monitoring, then the device structure is simple, but the detection sensitivity is insufficient (only 4 μg/ml protein detection)
Solution Approach 1:
The patent introduces fluorescently labeled nanoparticles as an intermediary between the Au-NHA sensor and the detection system. These nanoparticles enhance the optical signal through fluorescent labeling, enabling detection at clinically relevant concentrations (10 pg/ml for biotinylated BSA, 27 pg/ml for CRP) while maintaining the simplicity of the Au-NHA device structure
Solution Approach 2:
The patent changes the detection parameter from direct plasmonic signal monitoring to fluorescent signal detection. By using fluorescently labeled nanoparticles that bind to target analytes, the system transforms the detection mechanism to achieve higher sensitivity (detecting biomarkers at 10-27 pg/ml) while using a simpler optical read-out approach with standard fluorescence microscopy
2Measurement precision
If intensity imaging is used to miniaturize Au-NHA biosensors, then the device becomes more compact and portable, but the detection sensitivity remains insufficient for clinical concentrations
Solution Approach 1:
The patent uses fluorescently labeled nanoparticles as signal amplifiers that bind specifically to target biomarkers. This intermediary approach enables the detection of ultra-low biomarker concentrations (10-27 pg/ml) by converting weak plasmonic signals into strong fluorescent signals that can be detected with simple imaging equipment
Solution Approach 2:
The patent creates a composite detection system combining Au-NHA plasmonic structures with fluorescently labeled nanoparticles. This composite approach merges the advantages of both materials: the Au-NHAs provide selective binding and signal localization, while the fluorescent nanoparticles provide strong optical signals for sensitive detection at clinical concentration levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves highly sensitive and rapid detection of biomarkers, surpassing conventional methods by enabling single analyte resolution and multiplexed detection, with robust, low-cost manufacturing and real-time measurements, comparable to fluorescence amplification techniques like ELISA.
Implementation Method 1
visualizes single sub-wavelength nanoparticles under bright-field imaging, enabling digital quantification and localization of individual nanoparticle-labeled molecules through local extraordinary optical transmission quenching
Implementation Method 2
nanoplasmonic resonators, made of noble metals, couple the photon energy to the collective oscillations of the metal's free electrons, also known as surface plasmons, which interact with the biomolecules at the metal surface
Data Source
AI summary
The present invention relates to a plasmonic biosensor system. The system includes a nano-hole array device comprising at least one nano-hole array (NHA) including at least one or a plurality of nano holes (NH), an image sensor (A3) for capturing light provided by a light source (A1) and transmitted through the nano-hole array (NHA), and at least one or a plurality of nano-particles (NP) configured to be received by the nano-holes (NH) of the nano-hole array (NHA).